This website uses cookies to provide you with the best possible service. By continuing to use this website, you accept the use of cookies. However, you can change your browser’s cookie settings at any time. You can find further information in our updated data privacy statement.

Press Releases

Gen Re Announces 2018 U.S. Group Medical Evidence of Insurability Underwriting Survey Results

Issue: May 2018 | Life/Health North America

For immediate release
May 17, 2018

Portland, ME, May 17, 2018 … Gen Re has released results of its 2018 U.S. Group Medical Evidence of Insurability Underwriting Survey. The survey covers Group Life, LTD and STD products with a focus on how companies staff and process Evidence of Insurability (EOI) applications. It provides companies an opportunity to benchmark their results against those of the industry. Twenty insurance companies participated in this year’s survey.

Key observations include:

  • Participants reported receiving more than 1.8 million EOI applications per year.
  • The average processing time for an EOI application is 13 business days.
  • Although many companies reported having an automated EOI system, a significant amount of applications are still being reviewed by a medical underwriter.
  • The top challenges facing group medical underwriting departments are managing volumes during peak times and technology deficiencies.
     

For more information on this survey, or how you can participate in future surveys, please contact Heidi Alpren at halpren@genre.com.

________________________

Gen Re, a Berkshire Hathaway Company, is one of the leading life/health and property/casualty reinsurers in the world. Our North American life and health reinsurance company, General Re Life Corporation, has superior financial strength ratings among life and health reinsurers. Gen Re delivers tailor-made reinsurance programs and risk management solutions for the Life, AD&D, Medicare Supplement, Critical Illness and Disability markets. Through our research, we also offer valuable information and insights. For more information, visit www.genre.com.

 

Contact:

Heidi Alpren
Tel. + 1 207 347 4624